Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The object of this study is to assess the intra- and inter-individual variability of apoptosis and autophagy activities in women during pregnancy: 1 / in women with a normal pregnancy and 2 / in pregnant women particularly at risk of complications.
The study investigators hypothesize that there would be an intra-trophoblastic dialogue between the mechanisms of autophagy and apoptosis, the promotion of one partially inhibiting the other. The increase in trophoblastic autophagy during pregnancy could thus constitute an anti-apoptosis defense phenomenon, the exhaustion of which would lead to cellular apoptosis and to pathogenic consequences when it devastates the syncytiotrophoblast.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group A | without medical history or risk factors, with a normal pregnancy |
| |
| Group B | without medical history or risk factors, developing a pregnancy complication |
| |
| Group C | with risk of complication, having a normal pregnancy |
| |
| Group D | with a risk of complication, developing a pregnancy complication |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Blood test | Other | Blood samples taken to test levels of autophagy and apoptosis |
|
| Measure | Description | Time Frame |
|---|---|---|
| Potential autophagy induction activity in all groups | Microtubule-associated protein 1A/1B-light chain 3 fluorescence ratio | Day 0 |
| Potential autophagy induction activity in all groups | Microtubule-associated protein 1A/1B-light chain 3 fluorescence ratio | Month 1 |
| Potential autophagy induction activity in all groups | Microtubule-associated protein 1A/1B-light chain 3 fluorescence ratio | Month 2 |
| Potential autophagy induction activity in all groups | Microtubule-associated protein 1A/1B-light chain 3 fluorescence ratio | Month 3 |
| Potential autophagy induction activity in all groups | Microtubule-associated protein 1A/1B-light chain 3 fluorescence ratio | Month 4 |
| Potential autophagy induction activity in all groups | Microtubule-associated protein 1A/1B-light chain 3 fluorescence ratio | Month 5 |
| Potential autophagy induction activity in all groups | Microtubule-associated protein 1A/1B-light chain 3 fluorescence ratio | Delivery plus or minus 2 weeks (Month 6) |
| Measure | Description | Time Frame |
|---|---|---|
| Type of autophagy inhibition per patient in all groups | Early/late; measured by microtubule-associated protein 1A/1B-light chain 3 fluorescence ratio | Day 0 |
| Type of autophagy inhibition per patient in all groups |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
All pregnant women followed at the Nimes University Hospital for their pregnancy. Patients will be recruited among those consulting hospital gynecologists from the 3rd month of pregnancy but also through the circuit of specific gynecology-obstetrics consultations receiving in particular women with a history and / or risk factors for pathological pregnancy
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Sylvie Bouvier | CHU Nimes | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU de Nimes | Nîmes | France |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41371090 | Result | Fortier M, Portes M, Demattei C, Nouvellon E, Mercier E, Bourguignon C, Chea M, Gris JC, Letouzey V, Bouvier S. Thrombin generation reference values using the ST Genesia and STG-Thromboscreen assay in pregnant women. Thromb Res. 2026 Jan;257:109558. doi: 10.1016/j.thromres.2025.109558. Epub 2025 Nov 29. No abstract available. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006403 | Hematologic Tests |
| ID | Term |
|---|---|
| D019411 | Clinical Laboratory Techniques |
| D019937 | Diagnostic Techniques and Procedures |
| D003933 | Diagnosis |
| D008919 | Investigative Techniques |
Not provided
Not provided
Not provided
Not provided
Not provided
Plasma, serum and mononuclear blood cells
Early/late; measured by microtubule-associated protein 1A/1B-light chain 3 fluorescence ratio
| Month 1 |
| Type of autophagy inhibition per patient in all groups | Early/late; measured by microtubule-associated protein 1A/1B-light chain 3 fluorescence ratio | Month 2 |
| Type of autophagy inhibition per patient in all groups | Early/late; measured by microtubule-associated protein 1A/1B-light chain 3 fluorescence ratio | Month 3 |
| Type of autophagy inhibition per patient in all groups | Early/late; measured by microtubule-associated protein 1A/1B-light chain 3 fluorescence ratio | Month 4 |
| Type of autophagy inhibition per patient in all groups | Early/late; measured by microtubule-associated protein 1A/1B-light chain 3 fluorescence ratio | Month 5 |
| Type of autophagy inhibition per patient in all groups | Early/late; measured by microtubule-associated protein 1A/1B-light chain 3 fluorescence ratio | Delivery plus or minus 2 weeks (Month 6) |
| Potential apoptosis induction activity in all groups | % cells positive for Annexin V | Day 0 |
| Potential apoptosis induction activity in all groups | % cells positive for Annexin V | Month 1 |
| Potential apoptosis induction activity in all groups | % cells positive for Annexin V | Month 2 |
| Potential apoptosis induction activity in all groups | % cells positive for Annexin V | Month 3 |
| Potential apoptosis induction activity in all groups | % cells positive for Annexin V | Month 4 |
| Potential apoptosis induction activity in all groups | % cells positive for Annexin V | Month 5 |
| Potential apoptosis induction activity in all groups | % cells positive for Annexin V | Delivery plus or minus 2 weeks (Month 6) |
| Inter- and intra-individual apoptosis/autophagy ratio in all groups | Day 0 |
| Inter- and intra-individual apoptosis/autophagy ratio in all groups | Month 1 |
| Inter- and intra-individual apoptosis/autophagy ratio in all groups | Month 2 |
| Inter- and intra-individual apoptosis/autophagy ratio in all groups | Month 3 |
| Inter- and intra-individual apoptosis/autophagy ratio in all groups | Month 4 |
| Inter- and intra-individual apoptosis/autophagy ratio in all groups | Month 5 |
| Inter- and intra-individual apoptosis/autophagy ratio in all groups | Delivery plus or minus 2 weeks (Month 6) |
| Autophagy kinetics between groups | measured by microtubule-associated protein 1A/1B-light chain 3 fluorescence ratio | Day 0 |
| Autophagy kinetics between groups | measured by microtubule-associated protein 1A/1B-light chain 3 fluorescence ratio | Month 1 |
| Autophagy kinetics between groups | measured by microtubule-associated protein 1A/1B-light chain 3 fluorescence ratio | Month 2 |
| Autophagy kinetics between groups | measured by microtubule-associated protein 1A/1B-light chain 3 fluorescence ratio | Month 3 |
| Autophagy kinetics between groups | measured by microtubule-associated protein 1A/1B-light chain 3 fluorescence ratio | Month 4 |
| Autophagy kinetics between groups | measured by microtubule-associated protein 1A/1B-light chain 3 fluorescence ratio | Month 5 |
| Autophagy kinetics between groups | measured by microtubule-associated protein 1A/1B-light chain 3 fluorescence ratio | Delivery plus or minus 2 weeks (Month 6) |
| Apoptosis kinetics between groups | measured by % cells positive for Annexin V | Day 0 |
| Apoptosis kinetics between groups | measured by % cells positive for Annexin V | Month 1 |
| Apoptosis kinetics between groups | measured by % cells positive for Annexin V | Month 2 |
| Apoptosis kinetics between groups | measured by % cells positive for Annexin V | Month 3 |
| Apoptosis kinetics between groups | measured by % cells positive for Annexin V | Month 4 |
| Apoptosis kinetics between groups | measured by % cells positive for Annexin V | Month 5 |
| Apoptosis kinetics between groups | measured by % cells positive for Annexin V | Delivery plus or minus 2 weeks (Month 6) |
| Placental Growth Factor in each group | pg/ml measured by ELISA | Day 0 |
| Placental Growth Factor in each group | pg/ml measured by ELISA | Month 1 |
| Placental Growth Factor in each group | pg/ml measured by ELISA | Month 2 |
| Placental Growth Factor in each group | pg/ml measured by ELISA | Month 3 |
| Placental Growth Factor in each group | pg/ml measured by ELISA | Month 4 |
| Placental Growth Factor in each group | pg/ml measured by ELISA | Month 5 |
| Placental Growth Factor in each group | pg/ml measured by ELISA | Delivery plus or minus 2 weeks (Month 6) |
| Soluble fms-like tyrosine kinase-1 | pg/ml measured by ELISA | Day 0 |
| Soluble fms-like tyrosine kinase-1 | pg/ml measured by ELISA | Month 1 |
| Soluble fms-like tyrosine kinase-1 | pg/ml measured by ELISA | Month 2 |
| Soluble fms-like tyrosine kinase-1 | pg/ml measured by ELISA | Month 3 |
| Soluble fms-like tyrosine kinase-1 | pg/ml measured by ELISA | Month 4 |
| Soluble fms-like tyrosine kinase-1 | pg/ml measured by ELISA | Month 5 |
| Soluble fms-like tyrosine kinase-1 | pg/ml measured by ELISA | Delivery plus or minus 2 weeks (Month 6) |
| Constitutive thrombophilia | presence/absence of the prothrombin gene or factor V Leiden mutation, protein S, C or antithrombin deficiency | Day 0 |
| Acquired thrombophilia | Presence/absence of anti-phospholipid antibodies (lupus anticoagulant and/or anti beta2-GP1 and/or anti-cardiolipid). | Day 0 |
| Acquired thrombophilia | Presence/absence of anti-phospholipid antibodies (lupus anticoagulant and/or anti beta2-GP1 and/or anti-cardiolipid). | Month 1 |
| Acquired thrombophilia | Presence/absence of anti-phospholipid antibodies (lupus anticoagulant and/or anti beta2-GP1 and/or anti-cardiolipid). | Month 2 |
| Acquired thrombophilia | Presence/absence of anti-phospholipid antibodies (lupus anticoagulant and/or anti beta2-GP1 and/or anti-cardiolipid). | Month 3 |
| Acquired thrombophilia | Presence/absence of anti-phospholipid antibodies (lupus anticoagulant and/or anti beta2-GP1 and/or anti-cardiolipid). | Month 4 |
| Acquired thrombophilia | Presence/absence of anti-phospholipid antibodies (lupus anticoagulant and/or anti beta2-GP1 and/or anti-cardiolipid). | Month 5 |
| Acquired thrombophilia | Presence/absence of anti-phospholipid antibodies (lupus anticoagulant and/or anti beta2-GP1 and/or anti-cardiolipid). | Delivery plus or minus 2 weeks (Month 6) |
| Whole blood count | Day 0 |
| Whole blood count | Month 1 |
| Whole blood count | Month 2 |
| Whole blood count | Month 3 |
| Whole blood count | Month 4 |
| Whole blood count | Month 5 |
| Whole blood count | Delivery plus or minus 2 weeks (Month 6) |
| Renal function | creatinemia, proteinuria / creatinuria ratio | Day 0 |
| Renal function | creatinemia, proteinuria / creatinuria ratio | Month 1 |
| Renal function | creatinemia, proteinuria / creatinuria ratio | Month 2 |
| Renal function | creatinemia, proteinuria / creatinuria ratio | Month 3 |
| Renal function | creatinemia, proteinuria / creatinuria ratio | Month 4 |
| Renal function | creatinemia, proteinuria / creatinuria ratio | Month 5 |
| Renal function | creatinemia, proteinuria / creatinuria ratio | Delivery plus or minus 2 weeks (Month 6) |
| Fibrin levels | D dimers and fibrin monomers | Day 0 |
| Fibrin levels | D dimers and fibrin monomers | Month 1 |
| Fibrin levels | D dimers and fibrin monomers | Month 2 |
| Fibrin levels | D dimers and fibrin monomers | Month 3 |
| Fibrin levels | D dimers and fibrin monomers | Month 4 |
| Fibrin levels | D dimers and fibrin monomers | Month 5 |
| Fibrin levels | D dimers and fibrin monomers | Delivery plus or minus 2 weeks (Month 6) |
| Inflammation | C-reactive protein level | Day 0 |
| Inflammation | C-reactive protein level | Month 1 |
| Inflammation | C-reactive protein level | Month 2 |
| Inflammation | C-reactive protein level | Month 3 |
| Inflammation | C-reactive protein level | Month 4 |
| Inflammation | C-reactive protein level | Month 5 |
| Inflammation | C-reactive protein level | Delivery plus or minus 2 weeks (Month 6) |
| Activated partial thromboplastin time | seconds | Day 0 |
| Activated partial thromboplastin time | seconds | Month 1 |
| Activated partial thromboplastin time | seconds | Month 2 |
| Activated partial thromboplastin time | seconds | Month 3 |
| Activated partial thromboplastin time | seconds | Month 4 |
| Activated partial thromboplastin time | seconds | Month 5 |
| Activated partial thromboplastin time | seconds | Delivery plus or minus 2 weeks (Month 6) |
| Prothrombin time | seconds | Day 0 |
| Prothrombin time | seconds | Month 1 |
| Prothrombin time | seconds | Month 2 |
| Prothrombin time | seconds | Month 3 |
| Prothrombin time | seconds | Month 4 |
| Prothrombin time | seconds | Month 5 |
| Prothrombin time | seconds | Delivery plus or minus 2 weeks (Month 6) |
| Fibrinogen level | g/L | Day 0 |
| Fibrinogen level | g/L | Month 1 |
| Fibrinogen level | g/L | Month 2 |
| Fibrinogen level | g/L | Month 3 |
| Fibrinogen level | g/L | Month 4 |
| Fibrinogen level | g/L | Month 5 |
| Fibrinogen level | g/L | Delivery plus or minus 2 weeks (Month 6) |
| Thrombin generation time | seconds | Month 1 |
| Thrombin generation time | seconds | Month 2 |
| Thrombin generation time | seconds | Month 3 |
| Thrombin generation time | seconds | Month 4 |
| Thrombin generation time | seconds | Month 5 |
| Thrombin generation time | seconds | Delivery plus or minus 2 weeks (Month 6) |
| Thrombin generation time | seconds | Day 0 |
| fetal haemoglobin | g/L | Month 1 |
| fetal haemoglobin | g/L | Month 2 |
| fetal haemoglobin | g/L | Month 3 |
| fetal haemoglobin | g/L | Month 4 |
| fetal haemoglobin | g/L | Month 5 |
| fetal haemoglobin | g/L | Delivery plus or minus 2 weeks (Month 6) |